Adaptive study of the dose of the drug aldesleukin (interleukin-2) on regulatory T cells in type 1diabetes (DILT1D)

Study code
CBR77

Lead researcher
Dr Frank Waldron-Lynch

Study type
Participant re-contact

Institution or company
University of Cambridge

Researcher type
Academic

Speciality area
Diabetes

Recruitment Site
Cambridge

Summary

Type 1 diabetes is an autoimmune condition. 

The immune system (the body's natural defence against infection and illness) mistakes the cells in your pancreas as harmful and attacks them, destroying them completely or damaging them enough to stop them producing insulin.

This trial is using a drug -aldesleukin (interleukin-2) -that at low doses resets the immune system, to see if the destructive process can be halted in people with newly diagnosed type 1 diabetes, and if so, to determine the dose needed to do that.